Literature DB >> 28881143

Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.

Craig J Currie1,2, Sarah E Holden1, Ellen Berni1, David R Owens3.   

Abstract

OBJECTIVES: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic macular edema (DME) and fellow eyes not treated with FAc implant using data from the Iluvien Clinical Evidence study in the UK (ICE-UK) study.
METHODS: In this retrospective cohort study, data on people attending hospital eye services and treated with the FAc implant between April 1, 2013 and April 15, 2015 were collected. Changes in visual acuity (VA), central foveal thickness (CFT) and intraocular pressure (IOP) were compared between study eyes (intervention) and fellow eyes.
RESULTS: A total of 208 people were selected. Mean age was 68.1 years and 62% were male. Mean change in VA was -0.09 LogMAR units for study eyes and 0.04 LogMAR units for fellow eyes at 12 months post-implant (p < .001). Over the same period, ≥5 letter, ≥10 letter and ≥15 letter improvements in Early Treatment Diabetic Retinopathy Study (ETDRS) score were achieved by more FAc treated eyes than by fellow eyes (41% versus 23%, p < .001; 28% versus 11%, p < .001; and 18% versus 4%, p < .001 at 12 months, respectively). Differences in the mean change in CFT (-113 µm versus -13 µm, p < .001) and IOP (3.2 mmHg versus -0.2 mmHg, p < .001) were also observed between study and fellow eyes at 12 months.
CONCLUSION: Visual acuity improved in study eyes over the 12 months following FAc implant and worsened in fellow eyes. Over the same period, study eyes showed a larger improvement in central foveal thickness. Intraocular pressure worsened in study eyes only. Change in visual acuity, central foveal thickness and intraocular pressure between FAc implant and the end of the 12-month follow-up period differed significantly between study and fellow eyes.

Entities:  

Keywords:  Fluocinolone acetonide; diabetic macular edema; fellow eye; intraocular pressure; retrospective; study eye; visual acuity

Mesh:

Substances:

Year:  2017        PMID: 28881143     DOI: 10.1080/03007995.2017.1366659

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes.

Authors:  Raquel Estebainha; Raquel Goldhardt; Manuel Falcão
Journal:  Curr Ophthalmol Rep       Date:  2020-01-14

Review 2.  Current intravitreal therapy and ocular hypertension: A review.

Authors:  Aditya Sudhalkar; Alper Bilgic; Shail Vasavada; Laurent Kodjikian; Thibaud Mathis; Fransesc March de Ribot; Thanos Papakostas; Viraj Vasavada; Vaishali Vasavada; Samaresh Srivastava; Deepak Bhojwani; Pooja Ghia; Anand Sudhalkar
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

3.  Intravitreal Corticosteroid Implantation in Diabetic Macular Edema: Updated European Consensus Guidance on Monitoring and Managing Intraocular Pressure.

Authors:  Francisco J Goñi; Keith Barton; José António Dias; Michael Diestelhorst; Julián Garcia-Feijoo; Anton Hommer; Laurent Kodjikian; Massimo Nicolò
Journal:  Ophthalmol Ther       Date:  2022-01-05

4.  Effect of Extended Release Steroid Implants on the Contralateral Eye.

Authors:  Efrat Fleissig; Douglas Kenneth Sigford
Journal:  BMC Ophthalmol       Date:  2022-03-22       Impact factor: 2.209

Review 5.  Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.

Authors:  William Fusi-Rubiano; Rebecca R Blow; Mark Lane; Rupal Morjaria; Alastair K Denniston
Journal:  Ophthalmol Ther       Date:  2018-09-18

6.  Real-World Outcomes in Diabetic Macular Edema for the 0.2 µg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK.

Authors:  Bushra Mushtaq; Ajay Bhatnagar; Helen Palmer
Journal:  Clin Ophthalmol       Date:  2021-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.